Liver-specific SLC13A3 modulation alleviates MASLD by regulating NAD⁺ metabolism

Area of Science:

• Hepatology
• Molecular Biology
• Metabolic Diseases

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD), previously NAFLD, is a widespread liver condition with complex causes and few treatments.
• Understanding the molecular mechanisms driving MASLD is crucial for developing effective therapies.

Purpose of the Study:

• To investigate the role of the solute carrier SLC13A3 in the pathogenesis of MASLD.
• To determine if SLC13A3 can be a potential therapeutic target for MASLD.

Main Methods:

• Utilized a mouse model fed a high-fat, high-cholesterol, and high-fructose (HFHCHF) diet to study MASLD.
• Analyzed hepatic SLC13A3 expression levels and manipulated its expression (overexpression and knockdown) in liver cells.
• Performed targeted metabolomic analysis to understand molecular pathways affected by SLC13A3.

Main Results:

• Hepatic SLC13A3 expression was significantly increased in the MASLD mouse model and correlated with disease severity.
• Liver-specific overexpression of Slc13a3 worsened steatosis and metabolic dysfunction, while Slc13a3 knockdown improved these conditions.
• SLC13A3 was found to modulate hepatic NAD+ levels, affecting key lipid metabolism genes (SREBF1, CD36, PPARγ, SCD1).

Conclusions:

• SLC13A3 plays a critical, previously unrecognized role in regulating MASLD progression.
• Targeting SLC13A3 presents a potential novel therapeutic strategy for managing MASLD.